WallStreetZenWallStreetZen

NASDAQ: MRSN
Mersana Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MRSN

Based on 2 analysts offering 12 month price targets for Mersana Therapeutics Inc

Min Forecast
$30.00+9.37%
Avg Forecast
$30.38+10.74%
Max Forecast
$30.75+12.1%

Should I buy or sell MRSN stock?

Based on 2 analysts offering ratings for Mersana Therapeutics Inc.

Buy
Strong Buy
1 analysts 50%
Buy
0 analysts 0%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MRSN stock forecasts and price targets.

MRSN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-13
lockedlocked$00.00+00.00%2025-08-14

1 of 1

Forecast return on equity

Is MRSN forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is MRSN forecast to generate an efficient return on assets?

Company
-39.45%
Industry
93.69%
MRSN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MRSN earnings per share forecast

What is MRSN's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$8.88
Avg 2 year Forecast
-$10.65
Avg 3 year Forecast
-$10.48

MRSN revenue forecast

What is MRSN's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$25.8M-22.24%
Avg 2 year Forecast
$20.1M-39.44%
Avg 3 year Forecast
$11.4M-65.57%
MRSN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MRSN revenue growth forecast

How is MRSN forecast to perform vs Biotechnology companies and vs the US market?

Company
-28.63%
Industry
101.11%
Market
25.31%
MRSN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MRSN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MRSN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MRSN$27.43$30.38+10.74%Buy
NBY$1.09N/AN/A
COYA$6.51$15.80+142.70%Strong Buy
SPRO$2.40N/AN/A
UNCY$6.47$21.50+232.30%Buy
View Top Biotech Stocks

Mersana Therapeutics Stock Forecast FAQ

Is Mersana Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: MRSN) stock is to Buy MRSN stock.

Out of 2 analysts, 1 (50%) are recommending MRSN as a Strong Buy, 0 (0%) are recommending MRSN as a Buy, 1 (50%) are recommending MRSN as a Hold, 0 (0%) are recommending MRSN as a Sell, and 0 (0%) are recommending MRSN as a Strong Sell.

If you're new to stock investing, here's how to buy Mersana Therapeutics stock.

What is MRSN's earnings growth forecast for 2025-2027?

(NASDAQ: MRSN) Mersana Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.81%.

Mersana Therapeutics's earnings in 2025 is -$70,081,000.On average, 10 Wall Street analysts forecast MRSN's earnings for 2025 to be -$44,409,895, with the lowest MRSN earnings forecast at -$79,850,033, and the highest MRSN earnings forecast at -$8,187,953. On average, 10 Wall Street analysts forecast MRSN's earnings for 2026 to be -$53,237,187, with the lowest MRSN earnings forecast at -$83,377,151, and the highest MRSN earnings forecast at -$3,936,516.

In 2027, MRSN is forecast to generate -$52,372,404 in earnings, with the lowest earnings forecast at -$75,196,196 and the highest earnings forecast at -$16,375,905.

What is MRSN's revenue growth forecast for 2025-2027?

(NASDAQ: MRSN) Mersana Therapeutics's forecast annual revenue growth rate of -28.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.

Mersana Therapeutics's revenue in 2025 is $33,180,000.On average, 11 Wall Street analysts forecast MRSN's revenue for 2025 to be $128,972,749, with the lowest MRSN revenue forecast at $73,481,625, and the highest MRSN revenue forecast at $188,952,750. On average, 11 Wall Street analysts forecast MRSN's revenue for 2026 to be $100,444,883, with the lowest MRSN revenue forecast at $0, and the highest MRSN revenue forecast at $224,643,825.

In 2027, MRSN is forecast to generate $57,105,720 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $78,730,313.

What is MRSN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MRSN) forecast ROA is -39.45%, which is lower than the forecast US Biotechnology industry average of 93.69%.

What is MRSN's Price Target?

According to 2 Wall Street analysts that have issued a 1 year MRSN price target, the average MRSN price target is $30.38, with the highest MRSN stock price forecast at $30.75 and the lowest MRSN stock price forecast at $30.00.

On average, Wall Street analysts predict that Mersana Therapeutics's share price could reach $30.38 by Nov 13, 2026. The average Mersana Therapeutics stock price prediction forecasts a potential upside of 10.74% from the current MRSN share price of $27.43.

What is MRSN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MRSN) Mersana Therapeutics's current Earnings Per Share (EPS) is -$13.93. On average, analysts forecast that MRSN's EPS will be -$8.88 for 2025, with the lowest EPS forecast at -$15.97, and the highest EPS forecast at -$1.64. On average, analysts forecast that MRSN's EPS will be -$10.65 for 2026, with the lowest EPS forecast at -$16.68, and the highest EPS forecast at -$0.79. In 2027, MRSN's EPS is forecast to hit -$10.48 (min: -$15.04, max: -$3.28).

What is MRSN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MRSN) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.